DebraLRichardsonMD
Obstetrics & Gynecology • Oklahoma City, OKGynecologic Oncology
Associate Professor, Gynecologic Oncology at Stephenson Cancer Center
Dr. Richardson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
800 NE 10th St, Suite 5050
Oklahoma City, OK 73104- Is this information wrong?
Education & Training
Ohio State University/Mt Carmel HospitalFellowship, Gynecologic Oncology, 2006 - 2009
University of ConnecticutResidency, Obstetrics and Gynecology, 2001 - 2005
New York Medical CollegeClass of 2001
Certifications & Licensure
OK State Medical License 2017 - 2025
TX State Medical License 2009 - 2020
MN State Medical License 2005 - 2011
OH State Medical License 2006 - 2009- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Clinical Trials
- Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer Start of enrollment: 2020 Jun 29
Roles: Contact
- A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. Start of enrollment: 2022 Jul 25
Roles: Principal Investigator
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) Start of enrollment: 2022 Aug 31
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- 34 citationsAdvances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review.Debra L Richardson, Ramez N Eskander, David M O'Malley
JAMA Oncology. 2023-06-01 - 50 citationsRandomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An...David E. Cohn, Michael W. Sill, Joan L. Walker, David M. O'Malley, Christa Nagel
Gynecologic Oncology. 2017-09-01 - 197 citationsSociety of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositionsJohnathan M. Lancaster, C. Bethan Powell, Lee-may Chen, Debra L. Richardson
Gynecologic Oncology. 2015-01-01
Press Mentions
Mersana Therapeutics to Provide Update on the Progress of Its UpRi Clinical Development Strategy and Report Interim Data from the Ovarian Cancer Expansion Cohort of the UpRi Phase I StudySeptember 1st, 2021- Sarah Cannon to Present Latest Cancer Research Insights at 2021 ASCO® Annual MeetingJune 4th, 2021
- Group Is Established to Connect, Inspire and Empower UCI Women in TechnologyAugust 12th, 2020
- Join now to see all
Hospital Affiliations
OU HealthOklahoma City, Oklahoma
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
